197 related articles for article (PubMed ID: 23045281)
1. Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors.
Manchanda PK; Jones GN; Lee AA; Pringle DR; Zhang M; Yu L; La Perle KM; Kirschner LS
Oncogene; 2013 Jul; 32(30):3491-9. PubMed ID: 23045281
[TBL] [Abstract][Full Text] [Related]
2. Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.
Jones GN; Tep C; Towns WH; Mihai G; Tonks ID; Kay GF; Schmalbrock PM; Stemmer-Rachamimov AO; Yoon SO; Kirschner LS
Neoplasia; 2008 Nov; 10(11):1213-21. PubMed ID: 18953430
[TBL] [Abstract][Full Text] [Related]
3. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues.
Kirschner LS; Kusewitt DF; Matyakhina L; Towns WH; Carney JA; Westphal H; Stratakis CA
Cancer Res; 2005 Jun; 65(11):4506-14. PubMed ID: 15930266
[TBL] [Abstract][Full Text] [Related]
4. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
[TBL] [Abstract][Full Text] [Related]
5. NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation.
Bosco EE; Nakai Y; Hennigan RF; Ratner N; Zheng Y
Oncogene; 2010 Apr; 29(17):2540-9. PubMed ID: 20154721
[TBL] [Abstract][Full Text] [Related]
6. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit (PRKAR1A) in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas" (Carney complex).
Stratakis CA
Ann N Y Acad Sci; 2002 Jun; 968():3-21. PubMed ID: 12119264
[TBL] [Abstract][Full Text] [Related]
7. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma.
Chiasson-MacKenzie C; Vitte J; Liu CH; Wright EA; Flynn EA; Stott SL; Giovannini M; McClatchey AI
Nat Commun; 2023 Mar; 14(1):1559. PubMed ID: 36944680
[TBL] [Abstract][Full Text] [Related]
8. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1.
Mund JA; Park S; Smith AE; He Y; Jiang L; Hawley E; Roberson MJ; Mitchell DK; Abu-Sultanah M; Yuan J; Bessler WK; Sandusky G; Chen S; Zhang C; Rhodes SD; Clapp DW
J Biol Chem; 2020 Jul; 295(29):9948-9958. PubMed ID: 32471868
[TBL] [Abstract][Full Text] [Related]
9. Rac1 controls Schwann cell myelination through cAMP and NF2/merlin.
Guo L; Moon C; Niehaus K; Zheng Y; Ratner N
J Neurosci; 2012 Nov; 32(48):17251-61. PubMed ID: 23197717
[TBL] [Abstract][Full Text] [Related]
10. Interdomain binding mediates tumor growth suppression by the NF2 gene product.
Sherman L; Xu HM; Geist RT; Saporito-Irwin S; Howells N; Ponta H; Herrlich P; Gutmann DH
Oncogene; 1997 Nov; 15(20):2505-9. PubMed ID: 9395247
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.
Carroll SL
Acta Neuropathol; 2012 Mar; 123(3):321-48. PubMed ID: 22160322
[TBL] [Abstract][Full Text] [Related]
12. The importance of nerve microenvironment for schwannoma development.
Schulz A; Büttner R; Hagel C; Baader SL; Kluwe L; Salamon J; Mautner VF; Mindos T; Parkinson DB; Gehlhausen JR; Clapp DW; Morrison H
Acta Neuropathol; 2016 Aug; 132(2):289-307. PubMed ID: 27236462
[TBL] [Abstract][Full Text] [Related]
13. Use of mouse models to understand the molecular basis of tissue-specific tumorigenesis in the Carney complex.
Kirschner LS
J Intern Med; 2009 Jul; 266(1):60-8. PubMed ID: 19522826
[TBL] [Abstract][Full Text] [Related]
14. Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma.
Flaiz C; Ammoun S; Biebl A; Hanemann CO
Brain Pathol; 2009 Jan; 19(1):27-38. PubMed ID: 18445079
[TBL] [Abstract][Full Text] [Related]
15. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.
Bashour AM; Meng JJ; Ip W; MacCollin M; Ratner N
Mol Cell Biol; 2002 Feb; 22(4):1150-7. PubMed ID: 11809806
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients.
Rosenbaum C; Kluwe L; Mautner VF; Friedrich RE; Müller HW; Hanemann CO
Neurobiol Dis; 1998 Jul; 5(1):55-64. PubMed ID: 9702788
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
Fuse MA; Plati SK; Burns SS; Dinh CT; Bracho O; Yan D; Mittal R; Shen R; Soulakova JN; Copik AJ; Liu XZ; Telischi FF; Chang LS; Franco MC; Fernandez-Valle C
Mol Cancer Ther; 2017 Nov; 16(11):2387-2398. PubMed ID: 28775147
[TBL] [Abstract][Full Text] [Related]
18. A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas.
Caltabiano R; Magro G; Polizzi A; Praticò AD; Ortensi A; D'Orazi V; Panunzi A; Milone P; Maiolino L; Nicita F; Capone GL; Sestini R; Paganini I; Muglia M; Cavallaro S; Lanzafame S; Papi L; Ruggieri M
Childs Nerv Syst; 2017 Jun; 33(6):933-940. PubMed ID: 28365909
[TBL] [Abstract][Full Text] [Related]
19. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.
Lepont P; Stickney JT; Foster LA; Meng JJ; Hennigan RF; Ip W
Mutat Res; 2008 Jan; 637(1-2):142-51. PubMed ID: 17868749
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
